Dwight Moxie - 15 Mar 2023 Form 4 Insider Report for Revance Therapeutics, Inc.

Role: SVP, GC & Secretary
Signature: /s/ Dwight Moxie
Issuer symbol: N/A
Transactions as of: 15 Mar 2023
Net transactions value: -$224,664
Form type: 4
Filing time: 17 Mar 2023, 15:21:34 UTC
Previous filing: 02 Feb 2023
Next filing: 15 Aug 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RVNC	Common Stock	Tax liability	$224,664	-7,330	-13%	$30.65	48,217	15 Mar 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of a restricted stock awards (the"RSA") totaling 14,783 shares. 8,334 of the shares were issued pursuant to a RSA vested in three equal annual installments from March 15, 2020, and the remaining 6,449 shares were issued pursuant to a RSA that vests in three equal annual installments from March 15, 2021.

Content

Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of a restricted stock awards (the"RSA") totaling 14,783 shares. 8,334 of the shares were issued pursuant to a RSA vested in three equal annual installments from March 15, 2020, and the remaining 6,449 shares were issued pursuant to a RSA that vests in three equal annual installments from March 15, 2021.